$0.17
1.51% today
Nasdaq, Apr 02, 09:16 pm CET
ISIN
US45674E1091
Symbol
INAB
Sector
Industry

IN8bio Inc Stock price

$0.17
-0.09 33.58% 1M
-0.08 32.83% 6M
-0.08 32.85% YTD
-0.98 84.98% 1Y
-3.27 94.98% 3Y
-9.83 98.27% 5Y
-9.83 98.27% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
+0.01 4.04%
ISIN
US45674E1091
Symbol
INAB
Sector
Industry

Key metrics

Market capitalization $14.03m
Enterprise Value $7.94m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.86
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-29.60m
Free Cash Flow (TTM) Free Cash Flow $-24.34m
Cash position $11.12m
EPS (TTM) EPS $-0.62
P/E forward negative
Short interest 2.46%
Show more

Is IN8bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

IN8bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a IN8bio Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a IN8bio Inc forecast:

Buy
100%

Financial data from IN8bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 2.66 2.66
6% 6%
-
-2.66 -2.66
6% 6%
-
- Selling and Administrative Expenses 7.33 7.33
14% 14%
-
- Research and Development Expense 17 17
1% 1%
-
-27 -27
3% 3%
-
- Depreciation and Amortization 2.66 2.66
6% 6%
-
EBIT (Operating Income) EBIT -30 -30
2% 2%
-
Net Profit -30 -30
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about IN8bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IN8bio Inc Stock News

Neutral
GlobeNewsWire
2 days ago
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced today a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform at the American Association for Cancer Research (AACR) Annual...
Neutral
GlobeNewsWire
15 days ago
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360° (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA.
Neutral
GlobeNewsWire
20 days ago
Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free Expanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE) targeting CD19 for potential use in oncology and autoimmune diseases Continu...
More IN8bio Inc News

Company Profile

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Head office United States
CEO William Ho
Employees 18
Founded 2016
Website www.in8bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today